蛋白酶体是真核细胞中一种具多相催化活性的蛋白酶复合体,可降解大多数胞内蛋白,包括调节细胞周期和凋亡的关键蛋白。临床已验证,蛋白酶体可作为抗肿瘤治疗靶点,蛋白酶体抑制剂为新一类抗血液肿瘤药物。然而,某些蛋白酶体抑制剂[如已上市的多发性骨髓瘤(MM)标准治疗药borte-zom Proteasome is a heterogeneous catalytically active protease complex in eukaryotic cells that degrade most intracellular proteins, including key proteins that regulate cell cycle and apoptosis. Clinically proven, proteasome can be used as a target for anti-tumor therapy, proteasome inhibitors for a new class of anti-hematological tumor drugs. However, certain proteasome inhibitors [such as the borte-zom, a standard treatment for multiple myeloma [MM] already on the market]